Europe Fungus Outbreak: Risks and At-Risk Groups
- A multi-drug resistant fungus, Candidozyma auris (formerly Candida auris), is rapidly spreading in healthcare settings worldwide, posing a serious threat to vulnerable patients.
- Candidozyma auris is an emerging yeast that was first identified in 2009 in Japan according to the Centers for Disease Control and Prevention (CDC).
- auris can survive on surfaces and medical equipment for extended periods, facilitating its spread within healthcare facilities.This resilience, combined with its resistance to multiple antifungal drugs, makes it...
“`html
Candidozyma auris: A Growing Threat to Global Health
Table of Contents
A multi-drug resistant fungus, Candidozyma auris (formerly Candida auris), is rapidly spreading in healthcare settings worldwide, posing a serious threat to vulnerable patients. This article details the emergence, spread, risks, and ongoing efforts to combat this perilous pathogen.
What is candidozyma auris?
Candidozyma auris is an emerging yeast that was first identified in 2009 in Japan according to the Centers for Disease Control and Prevention (CDC). Initially misidentified as Candida species,it was later reclassified as Candidozyma auris due to genetic differences as reported by the European Center for Disease Prevention and Control (ECDC). The fungus is particularly concerning due to its ability to cause severe infections, often in individuals with compromised immune systems.
Unlike many other fungi, C. auris can survive on surfaces and medical equipment for extended periods, facilitating its spread within healthcare facilities.This resilience, combined with its resistance to multiple antifungal drugs, makes it a formidable challenge for infection control teams.
The Rapid Spread of C. auris
The number of reported C. auris cases has increased dramatically since its initial revelation. The ECDC reported zero cases in 2013, but by 2023, 1,346 cases had been identified across Europe as detailed in their recent survey.this exponential growth highlights the fungus’s ability to spread quickly and establish itself in healthcare environments.
The United States has also experienced a significant increase in C. auris cases. The CDC reported 57 cases in 2018, rising to 1,762 cases as of December 31, 2022 according to CDC data. the majority of these cases have been identified in Florida,Illinois,California,and New York.
| Year | US Cases (CDC) | European Cases (ECDC) |
|---|---|---|
| 2013 | 0 | 0 |
| 2018 | 57 | Not Available |
| 2022 | 1,762 | Not Available |
| 2023 | Data Pending | 1,346 |
The spread is believed to be facilitated by international travel and the movement of patients between healthcare facilities.
Who is at Risk?
Individuals with weakened immune systems are particularly vulnerable to C. auris infections. This includes patients with:
- Underlying medical conditions (e.g., diabetes, cancer)
- Recent surgery
- Prolonged hospital stays
- Central venous catheters or other invasive